Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22255144 | 0.76 | AAK1 (0.33) | AAK1 | |
| SCHEMBL19132988 | 0.76 | CYP2D6 (0.32) | CYP2D6CHRM1HRH1KCNH2BACE1 | |
| SCHEMBL22725661 | 0.75 | TSHR (0.38) | CYP2D6KCNH2 | |
| SCHEMBL18815276 | 0.75 | MAOA (0.42) | — | |
| SCHEMBL18559669 | 0.73 | NOS3 (0.35) | AAK1 | |
| SCHEMBL20758796 | 0.73 | ALDH1A1 (0.35) | CYP2D6AAK1 | |
| SCHEMBL9963324 | 0.73 | CYP2D6 (0.40) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL23843301 | 0.72 | NR3C2 (0.34) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL12388005 | 0.72 | CYP2D6 (0.39) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL469179 | 0.72 | CYP2D6 (0.39) | CYP2D6CHRM1HRH1KCNH2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-9795550-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | SAMUMED, LLC (US) | 2017-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | CYP2D6 3001/4885CHRM1 4469/4885HRH1 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.